Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Deal to Evaluate Accelr8's BACcel Platform Expires Without Further Extension

NEW YORK (GenomeWeb News) – A technology evaluation agreement between Accelr8 Technology and Novartis has expired without further extension by Novartis, Accler8 said today.

As a result, Accelr8 will be able to negotiate with other firms for its BACcel system.

The agreement between Accelr8 and Novartis began in June 2010 and expired on Sept. 30, 2011, after a series of extensions. The final extension gave Novartis the option to continue evaluating the BACcel system through Jan. 2, 2012.

With evaluation of the system ended, Accelr8 said, "discussion has now shifted to searching within Novartis for funding vehicles."

The BACcel system is a rapid bacterial diagnostics system that, according to the firm, can identify bacteria within two hours and their major resistance mechanisms within six hours. The firm has been working on tests for antibiotic resistance detection.

David Howson, president of Accelr8, said in a statement that a recent reorganization in the Novartis Vaccines and Diagnostics business has "delayed project decisions until the reorganization is completed." He added that Accelr8 is on a "rapid development path. To maintain momentum we are taking direct action to develop additional paths to finish the product development."

The company said it has been in discussions with other firms for "BACcel applications that complement clinical diagnostics, such as pharma development," and is now starting discussions with clinical diagnostic companies.

Howson said that Accelr8 continues to work with Novartis on studies with gram-negative organisms that express broad-spectrum resistance. "[W]e expect a corporate update from Novartis before Thanksgiving," he added.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.